Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
CA 2492964 C · Owner: Dermira (Canada), Inc. · Inventors: Yan, Jun; Daynard, Timothy S.; Chen, Jianxin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I): wherein R1 R2 and R3 at each , occurrence are independently selected from amino aminosulfinyl, aminosulfonyl, aryl, azido halogen, heteroalkyl, heteroaryl, hydrazinyl hydrocarbyl, hydrogen, hydroxyl, nitro nitroso, phosphate, phosphinate, phosphonate phosphonium, phosphorothioate, phosphoryl sulfamoyl, sulfate, sulfinic acid, sulfonamido sulfonate, sulfonic acid, sulfonyl, sulfoxido thiol, thioureido, and ureido, and R4 is selected from hydrogen heteroalkyl, heteroaryl, and hydrocarbyl is described as useful in treatment of disorders associated with dysregulation of cell …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 23, 2003 and granted July 17, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 23, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 23, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.